To Test or Re-Test, that is the Question: Comparison of the Mismatch Repair Deficiency between Primary and Recurrent Sites of Uterine Cancers (088)

医学 MSH2 MSH6型 子宫内膜癌 MLH1 子宫癌 肿瘤科 DNA错配修复 癌症 PMS2系统 内科学 原发性肿瘤 免疫组织化学 林奇综合征 病理 结直肠癌 转移
作者
Daniel Spinosa,Janice Wong,Regina S. Whitaker,Kyle C. Strickland,Rebecca A. Previs
出处
期刊:Gynecologic Oncology [Elsevier BV]
卷期号:166: S60-S60 被引量:6
标识
DOI:10.1016/s0090-8258(22)01313-0
摘要

Objectives: Mismatch repair deficiency (MMR-D) is a common genotype in uterine cancer with prognostic and therapeutic implications. Prior studies have demonstrated tumoral evolution with respect to MMR deficiency between primary and recurrent gastrointestinal cancers. Whether uterine cancers undergo similar clonal evolution between primary and recurrent sites is less well understood. The purpose of this study was to determine if MMR deficiency concordance exists between primary and recurrent disease sites in patients with uterine cancer who later develop recurrent disease. Methods: We identified patients with a history of primary and recurrent uterine cancer from a single high-volume cancer center. Histologic slides were reviewed to confirm the diagnosis of primary and recurrent cancer, and formalin-fixed paraffin-embedded tissue blocks were requested from archives. Immunohistochemistry (IHC) was performed using antibodies against mismatch repair proteins (MMR), including MLH1, PMS2, MSH2, and MSH6. Results: A total of 86 primary and recurrent matched specimens were identified from 43 patients. Eleven patients (26%) did not have sufficient tissue for analysis from the primary or recurrent site and were therefore excluded from the analysis. The majority (28/32, 88%) were at stage I at the time of diagnosis; 11/32 (34%) were high-grade epithelial, and 1/32 (3%) had carcinosarcoma. Based on IHC expression of MMR proteins, 6/32 (19%) of primary tumors had MMR deficiency (MMR-D), while 9/32 (28%) of recurrent tumors had MMR-D. All patients (6/6, 100%) with MMR-D tumors in the primary setting retained MMR-D in the recurrent setting, while 3/26 (12%) patients who were MMR proficient in the primary setting were MMR-D in the recurrent setting. Of patients with MMR-D, 5/6 (83%) were deficient due to no MLH1 and PMS2 in the primary tumor, while one tumor had no MSH2 and MSH6 expression. All six patients with MMR-D in the primary tumor had an identical IHC phenotype in the recurrent setting. Of patients whose tumor became MMR-D, 3/3 (100%) had a loss of MLH1, and 2/3 (67%) had a loss of PMS2. Two of the three patients (67%) who developed MMR-D were at grade 1 epithelial at the time of initial diagnosis. In total, 23/32 (72%) patients showed proficient expression in both the primary and recurrent tumors, and 29/32 (91%) had concordance between primary and recurrent tumors. Conclusions: Rates of MMR-D in the primary setting were 19%, consistent with rates previously reported. Patients with MMR-D uterine tumors in the primary setting are likely to remain MMR-D in the recurrent setting. We identified 12% of patients with recurrent uterine cancer who developed MMR-D in the recurrent setting. This clonal evolution represents a biomarker that has therapeutic implications for patients with recurrent uterine cancer. Objectives: Mismatch repair deficiency (MMR-D) is a common genotype in uterine cancer with prognostic and therapeutic implications. Prior studies have demonstrated tumoral evolution with respect to MMR deficiency between primary and recurrent gastrointestinal cancers. Whether uterine cancers undergo similar clonal evolution between primary and recurrent sites is less well understood. The purpose of this study was to determine if MMR deficiency concordance exists between primary and recurrent disease sites in patients with uterine cancer who later develop recurrent disease. Methods: We identified patients with a history of primary and recurrent uterine cancer from a single high-volume cancer center. Histologic slides were reviewed to confirm the diagnosis of primary and recurrent cancer, and formalin-fixed paraffin-embedded tissue blocks were requested from archives. Immunohistochemistry (IHC) was performed using antibodies against mismatch repair proteins (MMR), including MLH1, PMS2, MSH2, and MSH6. Results: A total of 86 primary and recurrent matched specimens were identified from 43 patients. Eleven patients (26%) did not have sufficient tissue for analysis from the primary or recurrent site and were therefore excluded from the analysis. The majority (28/32, 88%) were at stage I at the time of diagnosis; 11/32 (34%) were high-grade epithelial, and 1/32 (3%) had carcinosarcoma. Based on IHC expression of MMR proteins, 6/32 (19%) of primary tumors had MMR deficiency (MMR-D), while 9/32 (28%) of recurrent tumors had MMR-D. All patients (6/6, 100%) with MMR-D tumors in the primary setting retained MMR-D in the recurrent setting, while 3/26 (12%) patients who were MMR proficient in the primary setting were MMR-D in the recurrent setting. Of patients with MMR-D, 5/6 (83%) were deficient due to no MLH1 and PMS2 in the primary tumor, while one tumor had no MSH2 and MSH6 expression. All six patients with MMR-D in the primary tumor had an identical IHC phenotype in the recurrent setting. Of patients whose tumor became MMR-D, 3/3 (100%) had a loss of MLH1, and 2/3 (67%) had a loss of PMS2. Two of the three patients (67%) who developed MMR-D were at grade 1 epithelial at the time of initial diagnosis. In total, 23/32 (72%) patients showed proficient expression in both the primary and recurrent tumors, and 29/32 (91%) had concordance between primary and recurrent tumors. Conclusions: Rates of MMR-D in the primary setting were 19%, consistent with rates previously reported. Patients with MMR-D uterine tumors in the primary setting are likely to remain MMR-D in the recurrent setting. We identified 12% of patients with recurrent uterine cancer who developed MMR-D in the recurrent setting. This clonal evolution represents a biomarker that has therapeutic implications for patients with recurrent uterine cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
高大莺完成签到 ,获得积分10
1秒前
zzw发布了新的文献求助20
2秒前
幸福果汁完成签到,获得积分10
3秒前
量子星尘发布了新的文献求助10
3秒前
谢谢谢谢谢谢谢谢完成签到 ,获得积分10
4秒前
Akim应助biofresh采纳,获得30
4秒前
长安发布了新的文献求助10
5秒前
6秒前
zzw完成签到,获得积分10
11秒前
Guochunbao完成签到,获得积分10
12秒前
哈哈哈完成签到 ,获得积分10
14秒前
科研通AI5应助蒋念寒采纳,获得10
14秒前
月亮褪色了完成签到 ,获得积分20
18秒前
萱棚完成签到 ,获得积分10
18秒前
19秒前
Cao完成签到 ,获得积分10
19秒前
ENG完成签到,获得积分10
21秒前
alick完成签到,获得积分10
23秒前
刘刘完成签到,获得积分10
24秒前
Tom完成签到,获得积分10
25秒前
Villanellel发布了新的文献求助10
26秒前
程艳完成签到 ,获得积分10
27秒前
MINGHUI完成签到,获得积分10
28秒前
28秒前
子车半烟完成签到,获得积分10
28秒前
30秒前
淳于安筠完成签到,获得积分10
30秒前
雨晴完成签到,获得积分10
33秒前
jbq发布了新的文献求助10
33秒前
joshar完成签到,获得积分10
33秒前
34秒前
量子星尘发布了新的文献求助10
36秒前
blueblue完成签到,获得积分10
38秒前
落后秋烟完成签到,获得积分10
40秒前
大橙子发布了新的文献求助10
41秒前
LMY完成签到 ,获得积分10
41秒前
Betty完成签到 ,获得积分10
41秒前
NexusExplorer应助jbq采纳,获得10
42秒前
渔渔完成签到 ,获得积分10
42秒前
43秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022